Advances with surfactant.
In this article, the physiology of surfactant is reviewed along with the research that lead to its current clinical uses. Acute lung injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) will also be reviewed because they represent pulmonary disease processes in which secondary deficiency and surfactant inactivation occur, for which surfactant may prove to be an effective treatment. Finally, research using surfactant as a treatment for other pulmonary diseases, such as bronchiolitis and asthma, will be briefly highlighted. These studies may one day lead to new treatment opportunities in the realm of emergency medicine.
Turell
David C
DC
Pediatric Urgent Care, Department of General Pediatrics, Children's Hospital, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. turelld@ccf.org
D000818:Animals; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004635:Emergency Medicine / Q000639:trends*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D008471:Meconium Aspiration Syndrome / Q000188:drug therapy*; D011663:Pulmonary Surfactants / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D012128:Respiratory Distress Syndrome / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy* / Q000503:physiopathology*
D011663:Pulmonary Surfactants